A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
Li Zhang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Novartis
Honoraria - AstraZeneca; Aventis; Novartis; Roche
Research Funding - Aventis; Boehringer Ingelheim; GlaxoSmithKline; Novartis
Meiqi SHI
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Jian ping Xiong
No relevant relationships to disclose
Gongyan Chen
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Wenchao Liu
No relevant relationships to disclose
Yiping Zhang
No relevant relationships to disclose
Kai LI
No relevant relationships to disclose
Hao Yu
No relevant relationships to disclose
Haoyuan Jiang
Employment or Leadership Position - Ph.D., M.D., Medical Director